Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP-100 monotherapy in r/r CLL
NCT04704323Phase 1Recruiting
- Sponsor
- Catapult Therapeutics
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CAP-100 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Catapult Therapeutics. Primary endpoints: Incidence of treatment emergent adverse effects at increasing doses at 28 Days, Incidence of treatment emergent adverse effects of CAP-100 at RP2D at 28 Days and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
CAP-100
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04704323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704323.